A large new study following thousands of participants found that older people who stop taking statins have a significantly increased risk of hospital admission due to cardiovascular problems.
Statins are a class of drugs that people take to keep their blood cholesterol levels under control.
Aside from this, they also have another use — that of protecting against heart disease and other cardiovascular conditions and events.
However, statins’ effectiveness in protecting the heart health of older individuals has remained a matter of debate.
Knowing this, Dr. Philippe Giral, from Pitié-Salpêtrière Hospital in Paris, France, and a team of specialists set out to investigate how giving up statins could affect the health of healthy individuals aged 75 years and over.
“A particularly relevant practical question is whether existing statin therapy can be stopped in older people with no history of cardiovascular disease,” write Dr. Giral and colleagues in their study paper, which appeared today in the European Heart Journal.
“This issue,” the researchers add, “currently concerns a large proportion of the population over the age of 75 years, as well as large numbers of people under the age of 75 years, currently taking evidence-based treatment with statins and reaching ages for which only limited evidence of efficacy is available.”
In the current study, the team analyzed the health information of 120,173 participants living in France. All of these individuals reached the age of 75 years between 2012 and 2014, had no history of cardiovascular disease, and had been taking statins regularly in the 2 years prior to joining the study.
The team followed the participants’ health developments over a maximum of 4 years, with an average follow-up period of 2.4 years.
During this time, the researchers noted that 17,204 individuals (14.3% of the total number of participants) stopped taking statins altogether for at least 3 months. In total, 5,396 (4.5%) of the study participants had to go to the hospital due to cardiovascular issues.
The researchers found that people who stopped taking statins had a 33% increase in the risk of requiring hospital admission for cardiovascular problems.
More specifically, older people who discontinued statin use had a 46% higher risk of experiencing heart problems and a 26% higher risk of experiencing a vascular event, such as a stroke.
“We estimated that an extra 2.5 cardiovascular events per 100 people would occur within 4 years among those who discontinued their statins at the age of 75 years compared to those who continued taking their statins,” notes Dr. Giral.
Based on the study findings and the team’s ensuing estimates, Dr. Giral advises older individuals not to halt their statin treatment later in life. Equally, the researcher suggests that doctors encourage their patients to continue taking any prescribed statins as a preventive therapy.
“To patients, we would say that if you are regularly [taking] statins for high cholesterol, we would recommend you don’t stop the treatment when you are 75. To doctors, we would recommend not stopping statin treatment given for primary prevention of cardiovascular diseases in your patients aged 75.”
Dr. Philippe Giral
While they say that the current study’s findings provide some evidence to support the importance of statin use well into older age, the authors also caution that their investigation was observational. Thus, it shows an association between interrupting the use of statins and an increased risk of cardiovascular events.
Future work needs to determine whether this relationship is truly causational, the researchers note. Nevertheless, they believe that the current research can contribute to improving general guidelines regarding the use of statins as a preventive therapy.
“While we wait for results from randomized controlled trials, carefully conducted observational studies such as this can provide useful information for doctors and patients and can contribute to establishing more precise guidelines on the use of statins for primary prevention in the elderly,” says co-author Prof. Joël Coste.